ASSOCIATION OF SERUM BIOMARKERS WITH SEVERITY AND OUTCOMES OF ECLAMPSIA IN A TERTIARY CARE HOSPITAL

Main Article Content

Dr Shruti Gaur
Dr Arun Kumar Yadav
Dr. Arti Rai
Dr. Ayushi Shukla
Dr Avinash Tiwari

Keywords

Eclampsia; Serum biomarkers; LDH; Thrombocytopenia; Maternal outcomes; Perinatal outcomes; Hypertensive disorders of pregnancy.

Abstract

Eclampsia remains a major cause of maternal and perinatal morbidity and mortality in low- and middle-income countries. Early identification of women at risk of severe disease using easily available biochemical markers is crucial for appropriate management. This study aimed to evaluate the association of commonly measured serum biomarkers with the severity of eclampsia and related maternal and perinatal outcomes.


Methods: A cross-sectional observational study was conducted among 85 eclamptic women admitted to a tertiary care hospital between January and December 2024. Clinical data, biochemical parameters including LDH, uric acid, platelet count, AST, ALT, and serum creatinine were recorded. Disease severity was classified as mild–moderate or severe based on clinical and laboratory features. Maternal and perinatal outcomes were compared across biomarker categories. Data were analyzed using descriptive statistics, Chi-square test, and p < 0.05 was considered statistically significant.


Results: Elevated LDH (≥600 IU/L) was present in 49.41% of the participants and was significantly associated with severe eclampsia (67.74% vs. 31.48%; p = 0.001). Thrombocytopenia (<1,00,000/mm³) also showed a significant association with severe disease (22.58% vs. 7.41%; p = 0.043). Elevated uric acid, AST, ALT, and creatinine levels were more common in severe cases but did not reach statistical significance. High LDH levels were associated with recurrent seizures, ICU admission, acute kidney injury, and DIC. Severe eclampsia was linked to higher rates of preterm birth (61.29%), low birth weight (64.52%), and low 5-minute Apgar scores (35.48%).


Conclusion: LDH elevation and thrombocytopenia are strong predictors of severe eclampsia and adverse maternal outcomes, while other biochemical markers show limited utility when interpreted in isolation. Incorporating LDH and platelet count into routine clinical evaluation may enhance early risk stratification and improve maternal and perinatal outcomes, particularly in resource-limited settings.

Abstract 0 | PDF Downloads 0

References

1. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–33.
doi:10.1016/S2214-109X(14)70227-X.
2. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: WHO; 2018.
3. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–7.
doi:10.1053/j.semperi.2009.02.010.
4. Roberts JM, Hubel CA. The two-stage model of preeclampsia: variations on the theme. Placenta. 2009;30 Suppl A:S32–7.
doi:10.1016/j.placenta.2008.11.009.
5. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102(1):181–92.
doi:10.1016/S0029-7844(03)00475-7.
6. Qublan HS, Ammarin V, Bataineh O, Al-Shraideh Z, Tahat Y, Awamleh I, et al. Lactic dehydrogenase as a biochemical marker of adverse pregnancy outcome in severe pre-eclampsia. J Obstet Gynaecol Res. 2005;31(1):36–40.
doi:10.1111/j.1447-0756.2005.00238.x.
7. Jaiswar SP, Gupta A, Sharma N, Sinha S, Qureshi S. Lactic dehydrogenase: a biochemical marker for preeclampsia–eclampsia. J Obstet Gynaecol India. 2011;61(6):645–8.
doi:10.1007/s13224-011-0093-9.
8. Thangaratinam S, Ismail KM, Sharp S, Coomarasamy A, Khan KS. Predictive accuracy of uric acid for adverse maternal and perinatal outcomes in women with pre-eclampsia: systematic review and meta-analysis. BJOG. 2006;113(4):369–78.
doi:10.1111/j.1471-0528.2006.00889.x.
9. Shetty N, Shetty A. A study of serum LDH levels in preeclampsia and its correlation with maternal and perinatal outcome. Int J Reprod Contracept Obstet Gynecol. 2017;6(12):5459–63.
doi:10.18203/2320-1770.ijrcog20175212.
10. Zhang J, Zeisler J, Hatch MC, Berkowitz G. Epidemiology of pregnancy-induced hypertension. Epidemiol Rev. 1997;19(2):218–32.
doi:10.1093/oxfordjournals.epirev.a017954.
11. Sibai BM. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol. 2006;30(1):16–9.
doi:10.1053/j.semperi.2006.01.008.
12. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2020;135(6):e237–60.
13. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. NICE Guideline NG133. London: NICE; 2019.
14. Singh DK, Sinha N, Kumar R, Bhattacharya S, Maurya A. Identifying the risk factors for the prevention of hypertensive disorders in pregnancy in a tertiary care hospital: A cross-sectional study. J Family Med Prim Care 2020;9:6121-4.
15. Bhattacharya S, Saleem SM, Singh DK, Marzo RR, Singh A. Colour coded client segmentation (CCCS) public health approach to educate the community to deal with problem of hypertension: A pilot study. J Edu Health Promot 2021;10:41
16. Singh DK, Sinha N, Bera OP, Saleem SM, Tripathi S, Shikha D, et al. Effects of diet on hypertensive disorders during pregnancy: A cross-sectional study from a teaching hospital. J Family Med Prim Care 2021;10:3268-72.
17. Singh, A, et al."Pathological Features of Myocardial Infarction in Patients with Pre-existing Hypertension." European Journal of Cardiovascular Medicine, vol. 14, no. 4, 2024, pp. 942-947.
18. Khan F, Sinha N, Kumar R, Singh DK. Comparison of normal and abnormal CTG tracings in labour in terms of pregnancy and early neonatal outcome: Journal of Cardiovascular Disease Research2022;Vol13 Issue10:291-99